Your session is about to expire
← Back to Search
HAV vs AVF for Kidney Failure (HUMAXX Trial)
HUMAXX Trial Summary
This trial compares the success of two methods of dialysis access for patients with kidney failure.
HUMAXX Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowHUMAXX Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2009 Phase 3 trial • 4545 Patients • NCT00474526HUMAXX Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What potential adverse effects might patients in the HAV treatment arm experience?
"Our experts at Power believe HAV therapy is relatively safe, scoring a 3 on our risk scale. This judgment stems from the fact that this trial has reached its third phase of testing and various data points point to its efficacy and safety."
Are any new participants being accepted into this clinical experiment?
"This experiment, which was initially advertised on September 7th 2023 is still searching for participants as indicated by recent updates to the clinicaltrials.gov page (last update: 12/9/2023)."
What is the participation rate for this experiment?
"Yes, the clinicaltrials.gov website attests to this trial's on-going recruitment process that began on September 7th 2023 and was recently updated on 12th of September 2023. 150 patients need to be enrolled from only 1 centre."
What is the primary purpose of this investigation?
"According to the sponsor, Humacyte Inc., the primary outcome being measured over a 12 month period is the rate of infections related to any HD access. Along with this main objective, they are also assessing secondary outcomes such as Duration of functional patency of the SA over 12 months from randomization, Number of days free from indwelling catheter (catheter-free days)from randomization to 183 days (Month 6), and Number of days from study access (SA) maturation until abandonment."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger